| Identification | More | [Name]
Isradipine | [CAS]
75695-93-1 | [Synonyms]
4-(2,1,3-BENZOXADIAZOL-4-YL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINECARBOXYLIC ACID METHYL 1-METHYLETHYL ESTER
4-(4-BENZOFURAZANYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINEDICARBOXYLIC ACID METHYL 1-METHYLETHYL ESTER
Isradipin
4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid Methyl 1-Methylethyl Ester
Clivoten
DynaCirc
Esradin
Isrodipine
Lomir
PN-200-110
Presca
Prescal
4-(4-Benzofurazanyl)-2，6-dimethyl-1，4-dihydro-3，5-pyridinedicarboxylic acid methyl 1-methylethyl ester
Dynacrine
Iomir
Rebfiden
3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester
[R,(-)]-4-(Benzofurazan-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester
4-(Benzofurazan-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3-methyl 5-isopropyl ester
PN-200-100 | [EINECS(EC#)]
630-420-5 | [Molecular Formula]
C19H21N3O5 | [MDL Number]
MFCD00153820 | [Molecular Weight]
371.39 | [MOL File]
75695-93-1.mol |
| Chemical Properties | Back Directory | [Appearance]
Yellow Solid | [Melting point ]
166-1680C | [Boiling point ]
501.9±60.0 °C(Predicted) | [density ]
1.249±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C
| [solubility ]
DMSO: ~26 mg/mL
| [form ]
solid
| [pka]
2.56±0.70(Predicted) | [color ]
yellow
| [Usage]
Dihydropyridine calcium channel blocker. Antihypertensive; antianginal | [Merck ]
14,5240 | [BCS Class]
2/4 | [Stability:]
Stable for 2 years from date of purchsae as supplied. Protect from moisture. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | [InChIKey]
HMJIYCCIJYRONP-UHFFFAOYSA-N | [CAS DataBase Reference]
75695-93-1(CAS DataBase Reference) | [NIST Chemistry Reference]
Isradipine(75695-93-1) |
| Safety Data | Back Directory | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3
| [HS Code ]
2934990002 |
| Hazard Information | Back Directory | [Description]
Isradipine is a long-acting calcium blocker effective in the treatment of essential
hypertension. The advantages of isradipine as compared with other dihydropyridine
calcium antagonists include a "gentle" onset and fewer contraindications. It can be taken
by patients with diabetes mellitus, chronic obstructive airway diseases, gout, congestive
heart failure or ischemic heart disease. | [Chemical Properties]
Yellow Solid | [Originator]
Sandoz (Switzerland) | [Uses]
Dihydropyridine calcium channel blocker. Antihypertensive; antianginal | [Uses]
nonsedating H1-antihistamine | [Definition]
ChEBI: Isradipine is an isopropyl ester, a methyl ester, a dihydropyridine and a benzoxadiazole. | [Brand name]
Dynacirc (Reliant);Prescal. | [General Description]
Isradipine, 4-(4-benzofuranazyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid methyl 1-methylethyl ester (DynaCirc), is another second-generationdihydropyridine-type channel blocker. This drug, like theother second-generation analogs, is more selective for vascularsmooth muscle than for myocardial tissue. It is effectivein the treatment of stable angina, reducing the frequencyof anginal attacks and the need to use nitroglycerin. | [Biological Activity]
Potent and selective L-type voltage-gated Ca 2+ channel blocker. EC 50 and pA 2 values are 1.4 nM and 10.3 for relaxation of depolarization- and Ca 2+ -induced contractions of rabbit aorta respectively; EC 25 = 0.45 nM for reduction in rate of spontaneously beating guinea pig right atria. Long-acting antihypertensive agent in vivo , exerting primary effects on vascular tissue with secondary negative chronotropic action. | [Biochem/physiol Actions]
L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive. | [storage]
Store at -20°C | [References]
1) Bracht et al. (2001), Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia; J. Hyperten., 19 899
2) Chandra et al. (1999), Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia ; Pharmacology, 58 292
3) Merck 14:5240 |
|
|